$DBVT

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the...

DBV Technologies (NASDAQ:DBVT) shares fell 3.7% after the company filed to refresh its at-the-market offering program, enabling sales of up to $150 million in American Depositary Shares. DBV said net proceeds would mainly fund manufacturing expansion, biologics license applications for ages 1 to 7, and launch prep for Viaskin Peanut (age 4 to 7), if approved.

DBV Technologies said it filed an automatically effective SEC Form S-3ASR shelf registration to refresh its at-the-market program for sales of up to $150 million of American Depositary Shares. The ADSs represent five ordinary shares and the program is under a Sept. 5, 2025 sales agreement with Citizens JMP Securities. Net proceeds would fund manufacturing expansion, BLAs, Viaskin Peanut launch prep, development, and working capital.

DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d156695dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update • Continued productive engagement with the FDA in support of the BLA for the VI

DBV Technologies reported Q2 and half-year 2026 results. It said FDA engagement for the VIASKIN Peanut Patch BLA for children ages 4-7 continues, with BLA submission expected in Q3 2026 and no additional data requested. Cash and cash equivalents were $174.9 million at June 30, 2026, funding into Q3 2027. Net loss was $98.0 million for six months.

DBV Technologies (Euronext: DBV; Nasdaq: DBVT) published its half-year report on its AMF-regulated liquidity contract with ODDO BHF. Liquidity account assets rose from 41,159 shares and €432,367.25 (July 1, 2018) to 74,580 shares and €527,891.63 (Dec 31, 2025) and 146,321 shares and €396,088.22 (June 30, 2026). Jan 1–Jun 30, 2026: 1,989 buys and 2,012 sells; purchases 2,707,915 shares (€8.84m) and sales 2,636,174 shares (€8.70m).

A roundup of analysts’ June 30 price-target changes across many stocks. Examples: Wells Fargo raised AAL to $17 from $12; Leerink raised ABVX to $148 from $140; JPMorgan cut ACI to $20 from $22; Jefferies cut ALB to $211 from $244; Goldman cut APA to $32 from $34; KeyCorp raised ATI to $211 from $175.

DBV Technologies said it has been in iterative discussions with the FDA ahead of its BLA for the VIASKIN Peanut Patch in children aged 4–7. The FDA has not requested additional data, and DBV plans to incorporate feedback and submit the BLA in Q3 2026. A conference call is scheduled for June 29, 2026.

DBV Technologies said it has been added to Euronext’s Tech Leaders index, effective June 22, 2026. The index highlights high-growth European tech and adjacent sectors for institutional investors. DBV, a clinical-stage biopharma, develops the VIASKIN Peanut Patch for peanut allergy; the company said inclusion may increase awareness ahead of potential approval.

DBV Technologies said CEO Daniel Tassé will take part in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 9:20 a.m. ET in Miami. The company will webcast the session and provide a replay for 90 days on its investor events page.